Yahoo Finance • 15 hours ago
Key Points Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it’s one of her top holdings.10 stocks we like better than CRISPR Therapeutics... Full story
Yahoo Finance • 6 days ago
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. Thi... Full story
Yahoo Finance • 7 days ago
Key Points Healthcare investments tend to be less cyclical than other stocks and help diversify your portfolio. Vertex has a profitable portfolio and promising pipeline, and its growth may be just getting started. DexCom's foothold within... Full story
Yahoo Finance • 13 days ago
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, Stifel maintained a Hold rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The firm also k... Full story
Yahoo Finance • 13 days ago
Key Points Vertex's core business continues to drive strong financial results. The biotech has an exciting late-stage pipeline that could make significant progress in the next few years. 10 stocks we like better than Vertex Pharmaceutical... Full story
Yahoo Finance • 15 days ago
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. Thi... Full story
Yahoo Finance • 17 days ago
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $408 inflow -- that's a 0... Full story
Yahoo Finance • 22 days ago
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) presented new interim data for its investigational therapy povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) at the American Society of Nephrology (ASN) Ki... Full story
Yahoo Finance • 26 days ago
Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older CF drug. Continue Reading View Comments... Full story
Yahoo Finance • 27 days ago
Check out the companies making headlines in after-hours trading. Palantir Technologies — Shares of Palantir rose 1% in extended trading after the software company reported quarterly results that beat Wall Street's estimates , with governme... Full story
Yahoo Finance • 27 days ago
Key Points Netflix and Vertex benefit from strong pricing power that could come in handy if inflation increases. Both companies are leaders in their niche with excellent growth prospects. They could deliver market-beating returns through... Full story
Yahoo Finance • 28 days ago
Vertex Pharmaceuticals (VRTX) is gaining attention as new clinical data for its kidney disease therapy, povetacicept, shows encouraging results. The company’s portfolio is also benefiting from steady cystic fibrosis sales and early momentu... Full story
Yahoo Finance • 28 days ago
Key Points Vertex Pharmaceuticals has three key ways to deliver strong growth. Two factors about the biotech company are especially comforting. While Vertex faces the risk of pipeline setbacks, its late-stage track record is pretty good.... Full story
Yahoo Finance • 28 days ago
Vertex, Corteva, and many more will also report earnings. On the economic front, The Supreme Court will hear arguments on the legality of Trump’s tariffs, and ADP will release October employment data. Continue Reading View Comments... Full story
Yahoo Finance • last month
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on October 21, setting... Full story
Yahoo Finance • last month
Key Points Novo Nordisk's business is well-equipped to rebound in the GLP-1 market. Vertex is set to launch a couple of new medicines in the next few years. Both stocks look attractively valued relative to their growth potential. 10 stock... Full story
Yahoo Finance • last month
EXTON, PA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The membranous nephropathy (MN) treatment paradigm is on the brink of transformation, with physicians signaling strong interest in novel mechanisms of action and shifting away from legacy regi... Full story
Yahoo Finance • last month
BOSTON, October 27, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the UBS Global Healthcare Conference. Reshma Kewalramani, President and Chief Executive Officer will... Full story
Yahoo Finance • last month
Data center products and services company Vertiv (NYSE:VRT) will be reporting results this Wednesday morning. Here’s what investors should know. Vertiv beat analysts’ revenue expectations by 12% last quarter, reporting revenues of $2.64 b... Full story
Yahoo Finance • last month
E-MINI S&P (DECEMBER) / E-MINI NQ (DECEMBER) S&P, yesterday’s close: Settled at 6702.50, up 33.75 on Friday and 107.25 on the week NQ, yesterday’s close: Settled at 24,986.50, up 155.25 on Friday and 589.50 on the week E-mini S&P and E-... Full story